CTRI/2019/06/019703招募中3 期
Aldosterone blockade for Health Improvement Evaluation in End-stage renal disease - ACHIEVE
试验速览
- 阶段
- 3 期
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Age >=18 with a history of diabetes
- •2. On dialysis >= 90 days
- •3. On either
- •a. Hemodialysis prescribed at least 2 treatments per week or
- •b. Peritoneal dialysis prescribed with at least 1 exchange daily
- •4. Provides informed consent
排除标准
- •1. Hyperkalemia
- •a. Serum potassium >5.8 mmol/L in the 6 weeks prior to enrollment or
- •b. Serum potassium >6.0 mmol/L during active run-in
- •2. Currently taking and unable to withdraw a mineralocorticoid receptor
- •antagonist (i.e. spironolactone or eplerenone).
- •3. Known sensitivity or allergy to spironolactone
- •4. Current or planned pregnancy or breastfeeding
- •5. Scheduled living related donor renal transplant
- •6. Life expectancy < 6 months in the opinion of a treating nephrologist.
- •7. Enrolled in another interventional trial testing a mineralocorticoid receptor antagonist or drug that has a known or likely interaction with
- •spironolactone.
研究者
相似试验
尚未招募
4 期
se of aldosterone blockade to improve cardiac function in obesityDiastolic DysfunctionMyocardial fibrosisCardiovascular - Other cardiovascular diseasesACTRN12609000655246The University of Queensland120
进行中（未招募）
1 期
ALdosterone antagonist Chronic HEModialysis Interventional Survival Trialend-stage renal failure (ESRF)cardiovascular complicationMedDRA version: 20.0Level: PTClassification code 10007649Term: Cardiovascular disorderSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 20.0Level: LLTClassification code 10050441Term: Chronic renal insufficiencySystem Organ Class: 100000004857EUCTR2012-002856-18-BECHRU de Brest825
进行中（未招募）
不适用
ALdosterone antagonist Chronic HEModialysis Interventional Survival TrialEUCTR2012-002856-18-FRCHRU de Brest
已完成
不适用
Does aldosterone blockade improve endothelial dysfunction in patients with coronary artery disease but without heart failure?Coronary artery diseaseCirculatory SystemISRCTN70010120niversity of Dundee (UK)88
进行中（未招募）
1 期
Pilot study of aprepitant effect on aldosterone secretion in diabetic patient with hypertension associated with low reniDiabetic patient (diabetes mellitus) with hypertension associated with low reninMedDRA version: 18.1Level: HLTClassification code 10052741Term: Endocrine and metabolic secondary hypertensionSystem Organ Class: 100000004866MedDRA version: 18.1Level: PTClassification code 10012601Term: Diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2015-001501-14-FRRouen University Hospital20